Open an account

Bio-Techne

TECH · NASDAQ

$72.58+$0.09 (+0.12%)TodayMarket closed ·
Prev close $72.49

About TECH

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.

Employees
3,100
Headquarters
Minneapolis, Minnesota
Listed
Feb 9, 1989
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
bio-techne.com

TECH key statistics

Market cap
11.38B
Price-earnings ratio
62.49
Dividend yield
0.44%
Average volume
2.88M
Volume
3.21M
Open price
$72.48
High today
$72.61
Low today
$72.48
52 Week high
$72.69
52 Week low
$43.20

Bio-Techne (TECH) at a glance

As of Oct 20, 2026, Bio-Techne (TECH) shares are priced at $72.58, giving the company a market cap of 11.38B, a price-to-earnings ratio of 62.49 and a dividend yield of 0.44%.

Today the stock has traded between $72.48 and $72.61. The current price is 0.1% above the day's low and 0.0% below its high.

Volume so far is 3.21M shares, in line with the average of 2.88M shares a day.

Over the past year Bio-Techne has ranged from $43.20 to $72.69, and now sits 100% of the way up that range.

Bio-Techne met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.52 per share against an estimate of $0.5295.

The average analyst price target is $71.42, 1.6% below the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

15%of 13 analyst ratings say Buy
  • Buy15.4%
  • Hold84.6%
  • Sell0.0%
Price target · 14 analystsAvg $71.42
Low
$50.50
Now
$72.58
High
$78.75

TECH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 5.9% on average.

  1. Q3 FY24: reported $0.48 per share against an estimate of $0.4619
  2. Q4 FY24: reported $0.49 per share against an estimate of $0.504
  3. Q1 FY25: reported $0.42 per share against an estimate of $0.3898
  4. Q2 FY25: reported $0.42 per share against an estimate of $0.3941
  5. Q3 FY25: reported $0.56 per share against an estimate of $0.5216
  6. Q4 FY25: reported $0.53 per share against an estimate of $0.5089
  7. Q1 FY26: reported $0.53 per share against an estimate of $0.5483
  8. Q2 FY26: reported $0.52 per share against an estimate of $0.5295

TECH news

  • Press releasePRNewswire

    Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development

  • Press releasePRNewswire

    Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

  • Press releasePRNewswire

    Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD, TECH, CZR and CBAN

  • Press releasePRNewswire

    Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger - AUUD, TECH, CZR and CBAN

  • Press releasePRNewswire

    Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals

  • Press releaseBusiness Wire

    TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

Similar companies

Companies in the same industry as Bio-Techne

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.